邁克生物(300463.SZ)一季度淨利預增290%-330%
格隆匯4月9日丨邁克生物(300463.SZ)披露2021年第一季度業績預吿,公司預計2021年1-3月實現歸屬於上市公司股東的淨利潤2.95億元-3.25億元,同比增長290%-330%。
隨着國內抗擊新冠肺炎疫情工作的不斷推進,國內疫情防控成果不斷鞏固,報吿期內公司常規生化、免疫、臨檢等平台檢測產品的銷售快速恢復並實現較高增長;同時,由於後疫情時代經濟恢復對疫情防控的需求,公司新冠檢測產品在報吿期內仍保持高速增長態勢。公司經營管理層根據外部環境變化和內部發展需求積極調整經營策略,以豐富的產品、優質的服務獲得國內外終端客户的認可,促使公司本報吿期的經營業績較上年同期實現大幅度增長。
報吿期內,預計非經常性損益對淨利潤的影響為260萬元左右,主要系收到政府補助。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.